入院前抗高血压药物使用与脓毒症结局:血管紧张素转换酶抑制剂(ACEI)与血管紧张素受体阻滞剂(ARB)的影响
本研究利用台湾全民健康保险研究数据库的脓毒症队列,按年龄和性别频率匹配入院前使用抗高血压药物者(研究队列)与未使用者(对照队列),各33213例,主要终点为总住院死亡率。研究队列脓毒性休克诊断率(4.36% vs 2.31%,P<0.001)和总住院死亡率(38.42% vs 24.57%,P<0.001)均高于对照队列。在脓毒性休克条件下,入院前使用抗高血压药物与总住院死亡率调整OR降低相关(OR=0.66,95%CI 0.55-0.80),非休克条件下未观察到该关联。与未使用者相比,ACEI使用者(调整OR=0.93,95%CI 0.88-0.98)和ARB使用者(调整OR=0.85,95%CI 0.81-0.90)总住院死亡率调整OR降低,而CCB、β受体阻滞剂和利尿剂使用者未观察到。联合效应分析显示,ACEI(除外与利尿剂联用)和ARB使用与脓毒症总住院死亡率调整OR降低相关。
要点
- 在脓毒性休克患者中,入院前使用抗高血压药物与总住院死亡率调整OR降低相关(OR=0.66,95%CI 0.55-0.80),非休克条件下未观察到该关联。
- 与未使用者相比,ACEI使用者总住院死亡率调整OR=0.93(95%CI 0.88-0.98),ARB使用者调整OR=0.85(95%CI 0.81-0.90)。
- CCB、β受体阻滞剂和利尿剂使用者在整体脓毒症人群中未观察到总住院死亡率调整OR降低。
- 在脓毒性休克条件下,ACEI、ARB、CCB和β受体阻滞剂使用者均与总住院死亡率OR降低相关。
- 联合效应分析显示,ACEI(除外与利尿剂联用)和ARB使用与脓毒症总住院死亡率调整OR降低相关。
适用人群与场景
- 来自台湾全民健康保险研究数据库脓毒症队列的脓毒症患者,入院前使用抗高血压药物者(研究队列)与未使用者(对照队列)按年龄和性别频率匹配。
研究设计与关键结果
- 研究类型为基于台湾全民健康保险研究数据库脓毒症队列的匹配队列研究;研究队列33213例入院前使用抗高血压药物的脓毒症患者,对照队列为等量按年龄和性别频率匹配的未使用抗高血压药物的脓毒症患者。
- 研究队列脓毒性休克诊断率4.36% vs 对照队列2.31%(P<0.001),总住院死亡率38.42% vs 24.57%(P<0.001)。
- 在脓毒性休克条件下,入院前使用抗高血压药物与总住院死亡率调整OR降低相关(OR=0.66,95%CI 0.55-0.80),非脓毒性休克条件下未观察到该关联。
- 与未使用者相比,ACEI使用者总住院死亡率调整OR=0.93(95%CI 0.88-0.98),ARB使用者调整OR=0.85(95%CI 0.81-0.90);CCB、β受体阻滞剂和利尿剂使用者未观察到调整OR降低。
- 在脓毒性休克条件下,ACEI、ARB、CCB和β受体阻滞剂使用者均与总住院死亡率OR降低相关。
- 联合效应分析显示,ACEI使用(除外与利尿剂联用)与脓毒症总住院死亡率调整OR降低相关,ARB使用者观察到类似结果。
证据类型、等级与局限
- 证据类型为基于台湾全民健康保险研究数据库脓毒症队列的匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,入院前使用ACEI或ARB与总住院死亡率风险降低相关,无论患者处于非休克还是脓毒性休克状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Several studies have reported improved sepsis outcomes when certain preadmission antihypertensive drugs, namely, calcium channel blockers (CCBs), are used. This study aims to determine whether preadmission antihypertensive drug use, especially angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), is associated with decreased total hospital mortality in sepsis.
METHODS: This study was conducted using the unique database of a sepsis cohort from the National Health Insurance Research Database in Taiwan. Frequency matching for age and sex between preadmission antihypertensive drug users (study cohort) and nonusers (comparison cohort) was conducted. The primary outcome was total hospital mortality. Logistic regression analyses were performed to calculate the odds ratios (ORs) of important variables. Further joint effect analyses were carried out to examine the impacts of different combinations of antihypertensive drugs.
RESULTS: A total of 33,213 sepsis antihypertensive drug use patients were retrieved as the study cohort, and an equal number of matched sepsis patients who did not use antihypertensive drugs were identified as the comparison cohort. The study cohort had a higher incidence rate of being diagnosed with septic shock compared with the comparison cohort (4.36%-2.31%, P < 0.001) and a higher rate of total hospital mortality (38.42%-24.57%, P < 0.001). In the septic shock condition, preadmission antihypertensive drug use was associated with a decreased adjusted OR (OR = 0.66, 95% confidence interval [CI], 0.55-0.80) for total hospital mortality, which was not observed for the nonseptic shock condition. Compared with antihypertensive drug nonusers, both ACEI and ARB users had decreased adjusted ORs for total hospital mortality in sepsis (adjusted OR = 0.93, 95% CI, 0.88-0.98 and adjusted OR = 0.85, 95% CI, 0.81-0.90); however, CCB, beta-blocker, and diuretic users did not. In the septic shock condition, ACEI, ARB, CCB, and beta-blocker users all had decreased ORs for total hospital mortality. Joint effect analysis showed ACEI use, except in combination with diuretics, to be associated with a decreased adjusted OR for total hospital mortality in sepsis. Similar results were observed for ARB users.
CONCLUSIONS: Preadmission ACEI or ARB use is associated with a decreased risk of total hospital mortality, regardless of a nonshock or septic shock condition.
参考来源
- Hsieh MS, How CK, Hsieh VC, et al. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs). Shock. 2020. PMID: 31135703. doi:10.1097/SHK.0000000000001382
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。